Testosterone Cypionate Injection, USP, CIII, 200mg per mL, Rx only, 1mL Single-Dose Vial, Distri...
FDA Drug Recall #D-0363-2025 — Class II — April 10, 2025
Recall Summary
| Recall Number | D-0363-2025 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 10, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Eugia US LLC |
| Location | East Windsor, NJ |
| Product Type | Drugs |
| Quantity | 36,816 vials |
Product Description
Testosterone Cypionate Injection, USP, CIII, 200mg per mL, Rx only, 1mL Single-Dose Vial, Distributed by Eugia US LLC, E. Windsor, NJ, Manufactured by: Eugia Specialties Limited, Telangana State, India, NDC 55150-277-01
Reason for Recall
cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.
Distribution Pattern
Nationwide USA
Lot / Code Information
Lot #: 1TC24075A, Exp 11/30/2026.
Other Recalls from Eugia US LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0472-2025 | Class II | Gentamicin Injection, USP, (PEDIATRIC), 20 mg p... | May 29, 2025 |
| D-0389-2025 | Class II | Tirofiban Hydrochloride Injection 5 mg/100 mL (... | Apr 21, 2025 |
| D-0390-2025 | Class II | Tirofiban Hydrochloride Injection 12.5 mg/250 m... | Apr 21, 2025 |
| D-0186-2025 | Class II | Progesterone Injection USP, 500mg per 10 mL (50... | Dec 27, 2024 |
| D-0185-2025 | Class II | medroxyPROGESTERone Acetate Injectable Suspensi... | Dec 18, 2024 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.